Edition:
United States

Adverum Biotechnologies Inc (ADVM.OQ)

ADVM.OQ on NASDAQ Stock Exchange Global Market

3.30USD
1:04pm EST
Change (% chg)

$0.00 (+0.00%)
Prev Close
$3.30
Open
$3.35
Day's High
$3.35
Day's Low
$3.25
Volume
25,698
Avg. Vol
48,124
52-wk High
$4.20
52-wk Low
$2.45

Latest Key Developments (Source: Significant Developments)

Highbridge Capital Reports 5.55 Pct Passive Stake In Adverum Biotechnologies
Wednesday, 6 Dec 2017 05:37pm EST 

Dec 6 (Reuters) - Adverum Biotechnologies Inc ::HIGHBRIDGE CAPITAL MANAGEMENT LLC REPORTS 5.55 PERCENT PASSIVE STAKE IN ADVERUM BIOTECHNOLOGIES INC AS OF DECEMBER 5 - SEC FILING.  Full Article

Adverum Begins Patient Enrollment In Advance Phase 1/2 Clinical Trial
Tuesday, 5 Dec 2017 09:00am EST 

Dec 5 (Reuters) - Adverum Biotechnologies Inc ::ADVERUM BIOTECHNOLOGIES BEGINS PATIENT ENROLLMENT IN THE ADVANCE PHASE 1/2 CLINICAL TRIAL FOR A1AT DEFICIENCY.ADVERUM BIOTECHNOLOGIES INC - ‍COMPANY EXPECTS TO REPORT PRELIMINARY DATA IN SECOND HALF OF 2018​.  Full Article

‍Adage Capital Partners Reports A 5.55 Percent Passive Stake In Adverum Biotechnologies As Of Nov 17, 2017
Monday, 27 Nov 2017 10:51am EST 

Nov 27 (Reuters) - Adverum Biotechnologies Inc ::‍ADAGE CAPITAL PARTNERS GP, L.L.C REPORTS A 5.55 PERCENT PASSIVE STAKE IN ADVERUM BIOTECHNOLOGIES INC AS OF NOVEMBER 17, 2017 - SEC FILING​.  Full Article

Adverum Biotechnologies posts Q3 loss of $0.32 per share
Wednesday, 8 Nov 2017 04:01pm EST 

Nov 8 (Reuters) - Adverum Biotechnologies Inc :Adverum biotechnologies reports third quarter 2017 financial results and provides corporate update.Q3 loss per share $0.32.Q3 earnings per share view $-0.29 -- Thomson Reuters I/B/E/S.Adverum biotechnologies - ‍cash, cash equivalents,marketable securities were $186.6 million as of sept 30, 2017, versus $197.4 million as of june 30, 2017 ​.Adverum biotechnologies - ‍current cash position expected to fund 3 lead gene therapy programs through end of 2019.  Full Article

Adverum Biotechnologies Q2 loss per share $0.27
Tuesday, 8 Aug 2017 04:01pm EDT 

Aug 8 (Reuters) - Adverum Biotechnologies Inc :Adverum Biotechnologies reports second quarter 2017 financial results and provides update.Q2 loss per share $0.27.  Full Article

Adverum Biotechnologies Q1 loss per share $0.38
Tuesday, 9 May 2017 04:00pm EDT 

May 9 (Reuters) - Adverum Biotechnologies Inc :Adverum Biotechnologies reports first quarter 2017 financial results and provides update.Q1 loss per share $0.38.  Full Article

Adverum Biotechnologies on March 16, reached agreement in principle to settle consolidated securities class action lawsuit
Monday, 20 Mar 2017 04:23pm EDT 

Adverum Biotechnologies Inc : Adverum Biotechnologies- on March 16, reached agreement in principle to settle consolidated securities class action lawsuit .Adverum Biotechnologies Inc - proposed aggregate pre-tax amount of settlement is $13 million - sec filing.  Full Article

Adverum Biotechnologies Q4 loss per share $0.54
Monday, 6 Mar 2017 09:00am EST 

Adverum Biotechnologies Inc : Adverum Biotechnologies reports fourth quarter and full year 2016 financial results and provides update . Q4 loss per share $0.54 . Q4 earnings per share view $-0.30 -- Thomson Reuters I/B/E/S . Qtrly collaboration and license revenue $488,000 versus $960,000 . Adverum Biotechnologies Inc - for ADVM-043, co is planning to engage with FDA to review development plans under an open ind in first half of 2017 .Adverum Biotechnologies- cash and cash equivalents of $222.2 million as of Dec 31, 2016 expected to fund 3 lead gene therapy programs through end of 2019.  Full Article

Adverum says Regeneron Pharma elects to extend research term of deal
Wednesday, 1 Mar 2017 04:59pm EST 

Adverum Biotechnologies Inc : Adverum Biotechnologies-on Feb 23, Regeneron Pharma notified Adverum Biotechnologies of election to extend research term of collaboration, licensing deal .Adverum Biotechnologies - Regeneron Pharma elected to extend research term of deal for additional three years, through May 1, 2020.  Full Article

Adverum Biotechnologies provides update on Alpha-1 antitrypsin deficiency program
Friday, 14 Oct 2016 07:01am EDT 

Adverum Biotechnologies Inc : Adverum Biotechnologies provides update on alpha-1 antitrypsin deficiency program . Expects to begin enrolment of patients in phase 1/2 clinical trial for advm-043 in Q4 of 2017. . Adverum Biotechnologies Inc - decided to upgrade advm-043 manufacturing process by implementing its proprietary baculovirus-based production system . Adverum Biotechnologies Inc - company now expects to begin enrolment of patients in phase 1/2 clinical trial for advm-043 in Q4 of 2017 . Plans to transfer third-party contract manufacturing for advm-043 to a large-scale contract manufacturer . Adverum Biotechnologies Inc - goal is to meet with FDA to review modified plans in Q1 of 2017 .Adverum Biotechnologies - other lead programs for wamd and hae remain on target to initiate toxicology studies in first half of 2017.  Full Article

BRIEF-Highbridge Capital Reports 5.55 Pct Passive Stake In Adverum Biotechnologies

* HIGHBRIDGE CAPITAL MANAGEMENT LLC REPORTS 5.55 PERCENT PASSIVE STAKE IN ADVERUM BIOTECHNOLOGIES INC AS OF DECEMBER 5 - SEC FILING Source text for Eikon: (http://bit.ly/2iwSEnw) Further company coverage: